Bio-Bridge Science completes Chinese vaccines facility
US vaccines developer Bio-Bridge Science has completed the construction of a state-of-the-art GMP research and manufacturing facility located in Beijing. The facility will provide a high quality research and production environment for the company's vaccine products as well as pre-clinical and clinical trials.
US vaccines developer Bio-Bridge Science has completed the construction of a state-of-the-art GMP research and manufacturing facility located in Beijing. The facility will provide a high quality research and production environment for the company's vaccine products as well as pre-clinical and clinical trials.
The first phase of the plant consists of an area 2,200m2, which includes the main facility, where research and production will take place. The research area consists of an 815m2 clean air surface area. This area includes a 470m2 100,000 purity grade clean air environment, and a 345m2 10,000 purity grade clean air environment. Within this area there will also be several 100 purity grade clean air environments.
The facility also includes a 750m2 general working area and a 435m2 electricity and water area.
The interior and exterior construction was completed according to GMP rules and requirements; however, construction of the high and low voltage electricity and installation of steam equipment is still taking place with local suppliers.
Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV vaccine that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by Bio-Bridge ceo Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV.
The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV vaccines. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine.
"We are pleased to have completed the initial stage of development for this state-of-the-art facility," said Dr Liang Qiao. "This facility will allow us to produce the first HIV vaccine in China, develop additional vaccines for cervical and colon cancers and to accelerate many of our research activities."